```
=> b reg
FILE 'REGISTRY' ENTERED AT 17:02:31 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 JAN 2008  HIGHEST RN 1000370-19-3
DICTIONARY FILE UPDATES:  21 JAN 2008  HIGHEST RN 1000370-19-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l8
L1              STR
```




```
VAR G1=O/S
REP G2=(1-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L3         2510 SEA FILE=REGISTRY SSS FUL L1
L4              STR
```




```
VAR G1=O/S
REP G2=(1-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E4 C  E2 N  AT  16

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  16
```

```
STEREO ATTRIBUTES: NONE
L6          161 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7          143 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND 46.150.18/RID
L8          140 SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 AND NC2NC2/ES


=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:02:42 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Jan 2008  VOL 148 ISS 4
FILE LAST UPDATED: 21 Jan 2008  (20080121/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs fhitstr hitrn l19 tot
```

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1354308 HCAPLUS
DN 146:100725
TI Preparation of anilino pyrimidine derivatives for treatment of Hepatitis C virus
IN Kim, Jong Woo; Lee, Sang Wook; Lee, Geun Hyung; Han, Jae Jin; Park, Sang Jin; Park, Eul Yong; Shin, Joong Chul
PA B & C Biopharm. Co., Ltd., S. Korea
SO PCT Int. Appl., 49pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2006137706	A1	20061228	2006WO-KR02416	20060622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR----700676	B1	20070328	2005KR-0054885	20050624
PRAI 2005KR-0054885	A	20050624		

OS MARPAT 146:100725
GI



AB Title compds. represented by the formula I [wherein R1 = -N(R2)-(CH2)n-R3, 4-R4-(Het)-1-yl or (un)substituted heteroaryl; R2 = H, benzyl or alkyl; R3 = H, halo, OH, etc.; R4 = H, carbamoyl, alkyl, etc.; n = 0-4; Het = piperazine or piperidine; and pharmaceutically acceptable salts thereof] were prepared For example, I (R1 = MeNH) was provided in a multi-step synthesis starting from the reaction of 4,6-dichloro-2-(methylthio)pyrimidine with 4-(morpholino)aniline. The prepared title compds. showed inhibitory effect on activity of HCV RNA polymerase in vitro and low toxicity, thus can be advantageously used as a therapeutic or prophylactic agent of hepatitis C..
IT 917594-57-1P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[(piperidino)carbonyl]methyl]piperazin-1-yl]pyrimidine
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilino pyrimidine derivs. for treatment of Hepatitis C virus)
RN 917594-57-1 HCAPLUS

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Ethanone, 2-[4-[2-(methylthio)-6-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-1-piperazinyl]-1-(1-piperidinyl)- (CA INDEX NAME)



IT 917594-57-1P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[(piperidino)carbonyl]methyl]piperazin-1-yl]pyrimidine
917594-58-2P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[(4-methylpiperidino)carbonyl]methyl]piperazin-1-yl]pyrimidine
917594-59-3P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[(4-hydroxymethylpiperidino)carbonyl]methyl]piperazin-1-yl]pyrimidine
917594-60-6P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[(4-carbamoylpiperidino)carbonyl]methyl]piperazin-1-yl]pyrimidine
917594-61-7P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[4-(1-pyrrolidinyl)piperidino]carbonyl]methyl]piperazin-1-yl]pyrimidine
917594-62-8P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[[4-(piperidino)piperidino]carbonyl]methyl]piperazin-1-yl]pyrimidine
917594-63-9P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-[[[4-(morpholino)piperidino]carbonyl]methyl]piperazin-1-yl]pyrimidine
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilino pyrimidine derivs. for treatment of Hepatitis C virus)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:470969 HCAPLUS
DN 143:26636
TI Preparation of 4-[(Arylmethyl)aminomethyl]piperidines as inhibitors of NGF binding (nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR related diseases
IN Bosch, Michael; Wagnon, Jean
PA Sanofi-Synthelabo, Fr.
SO Fr. Demande, 31 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR---2862968	A1	20050603	2003FR-0014172	20031201
FR---2862968	B1	20060804		
WO2005054229	A1	20050616	2004WO-FR03066	20041130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP---1694668	A1	20060830	2004EP-0805590	20041130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
JP2007512384	T	20070517	2006JP-0541974	20041130
US2007037819	A1	20070215	2006US-0420505	20060526
PRAI 2003FR-0014172	A	20031201		
2004WO-FR03066	W	20041130		

OS MARPAT 143:26636
GI



I



II

AB Title compds. I [wherein X = (CH2)n; n = 1-2; R1 = CF3; R2 = H, alkyl; R3 = (un)substituted pyrrolyl, 1,2,3-thiadiazolyl, pyrazinyl, etc.; and their

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
salts, hydrates and solvates] were prepd. as inhibitors of the binding of 125I NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, II was prepd. by reacting 1-[4-(aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (prepn. given) and 1-methyl-2-pyrrolecarboxaldehyde in THF in the presence of NaBH(OAc)3/AcOH. I inhibited the binding of 125I NGF to p75NTR receptor with IC50 in the range of 10-11 M to 10-6 M at the biochem. level. I inhibited the pro-apoptic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC50 in the range of 10-11 M to 10-6 M at the cellular level.
IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)
RN 852936-29-9 HCAPLUS
CN 4-Piperidinemethanamine, N-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-32-4P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(1,3-thiazol-2-yl)methyl]methanamine trihydrochloride 852936-33-5P, (2-Furylmethyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-34-6P, (3-Furylmethyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-35-7P, [(5-Methyl-2-furyl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-36-8P, [(4,5-Dimethyl-2-furyl)methyl](methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine trihydrochloride 852936-37-9P, [(5-Chloro-2-furyl)methyl](methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-38-0P, [[1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl][(2-thienyl)methyl]amine 852936-39-1P, [[1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl][(3-thienyl)methyl]amine 852936-40-4P, 1-Phenyl-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]methanamine 852936-41-5P, [[1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl][(pyridin-2-yl)methyl]amine 852936-42-6P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-2-yl)methyl]methanamine 852936-43-7P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-3-yl)methyl]methanamine tetrahydrochloride 852936-44-8P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-4-yl)methyl]methanamine tetrahydrochloride 852936-45-9P, N-Methyl-1-(pyrazin-2-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]methanamine tetrahydrochloride 852936-46-0P, [(6-Methylpyridin-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-47-1P
, [(3-Methyl-2-thienyl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-
4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine trihydrochloride
852936-48-2P 852936-49-3P, N-Methyl-1-[1-[[4-(pyrazin-2-
yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-
[(pyrimidin-5-yl)methyl]methanamine 852936-50-6P,
(1H-Imidazol-2-ylmethyl)(methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-
yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine
852936-51-7P, (1H-Imidazol-5-ylmethyl)(methyl)[[1-[[4-(pyrazin-2-
yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-
yl]methyl]amine tetrahydrochloride 852936-52-8P,
N-Methyl-1-(4-methyl-1H-imidazol-5-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-
yl]acetyl]-4-[3-(trifluoromethyl)phenyl]pyridin-4-yl]methyl]methanamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; prepn. of 4-[(arylmethyl)aminomethyl]piperidines as
NGF binding inhibitors to p75NTR receptor and of the apoptosis induced
by NGF)
IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-
piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-
(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-
1-ethanone 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-
piperazinyl]ethanoyl]-4-[3-(trifluoromethyl)phenyl]-4-
piperidinyl]methyl]carbamate 852936-54-0P, tert-Butyl
[[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-
(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF
binding inhibitors to p75NTR receptor and of the apoptosis induced by
NGF)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:991506 HCAPLUS
DN 140:27846
TI Preparation of piperazinylacylpiperidines as inhibitors of NGF binding
(nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating
p75NTR related diseases
IN Bono, Francoise; Bosch, Michael; Dos, Santos Victor; Herbert, Jean Marc;
Nisato, Dino; Tonnerre, Bernard; Wagnon, Jean
PA Sanofi-Synthelabo, Fr.; Dos Santos, Victor
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2003104225	A1	20031218	2003WO-FR01685	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2487840	A1	20031218	2003CA-2487840	20030605
AU2003255644	A1	20031222	2003AU-0255644	20030605
EP---1513835	A1	20050316	2003EP-0757108	20030605
EP---1513835	B1	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR2003011828	A	20050329	2003BR-0011828	20030605
CN---1675203	A	20050928	2003CN-0818808	20030605
JP2005534661	T	20051117	2004JP-0511295	20030605
AT----325122	T	20060615	2003AT-0757109	20030605
NZ----537044	A	20060831	2003NZ-0537044	20030605
AT----336491	T	20060915	2003AT-0757108	20030605
PT---1513836	T	20060929	2003PT-0757109	20030605
ES---2264001	T3	20061216	2003ES-3757109	20030605
ES---2271637	T3	20070416	2003ES-3757108	20030605
US2005176722	A1	20050811	2004US-0516704	20041202
ZA2004009823	A	20060726	2004ZA-0009823	20041203
NO2004005331	A	20050307	2004NO-0005331	20041206
IN2004KN01862	A	20060407	2004IN-KN01862	20041206
MX2004PA12341	A	20050930	2004MX-PA12341	20041207
PRAI 2002FR-0007001	A	20020607		
2003WO-FR01685	W	20030605		

OS MARPAT 140:27846
GI

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [wherein: Y = (CH2)n; n = 1 or 2; X = (CH2)p; p = 1 or 2; R1 = halo, CF3, alkyl, alkoxy, trifluoromethoxy; R2 = H, halo; R3 = H, OR5, CH2OR5, NH2 and derivs., NHCOR6 and derivs., NHCONH2 and derivs., CH2NR7R8, CH2NHCONH2 and derivs., alkoxycarbonyl, CONH2 and derivs.; or R3 forms a double bond between the carbon atom where it is bound to and the neighboring carbon atom of the piperidine cycle; R4 = (un)substituted pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, 3(2H)-pyridazinon-5-yl, 3(2H)-pyridazinon-4-yl; R5 = H, alkyl, alkylcarbonyl; R6 = alkyl, (CH2)mNH2 and derivs.; m = 1,2, or 3; R7, R8 = independently H, alkyl; R8 = (CH2)qOH, (CH2)qSMe; q = 2 or 3; or R7R8N = aziridine, azetidine, pyrrolidine, piperidine, morpholine; and their salts, hydrates and solvates] were prepared as inhibitors of the binding of 125I NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, II•HCl was prepared by reacting 1-(2-pyrazinyl)piperazine (preparation given) with 2-chloro-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone (preparation given) in the presence of KI/K2CO3/MeCN, followed by acidulation with HCl. I inhibited the binding of 125I NGF to p75NTR receptor with IC50 in the range of 10-11 M to 10-6 M at the biochem. level. I inhibited the pro-apoptic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC50 in the range of 10-11 M to 10-6 M at the cellular level.

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

RN 634461-23-7 HCAPLUS

CN 4-Piperidinemethanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634461-63-5P 634461-69-1P 634462-72-9P
634462-91-2P 634463-08-4P 634463-19-7P
634463-39-1P 634463-49-3P 634464-60-1P
634464-66-7P 634525-03-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(NGF binding inhibitor; prepn. of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride
634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-(pyrazinyl))-1-piperazinyl]-1-propanone oxalate
634461-29-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]-1-ethanone
Trihydrochloride 634461-52-2P 634461-57-7P
634461-73-7P 634461-76-0P 634461-81-7P
634461-87-3P 634461-93-1P 634461-99-7P
634462-26-3P 634462-32-1P 634462-38-7P
634462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]-1-ethanone dioxalate
634462-55-6P 634462-61-6P 634462-68-3P
634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P,
1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate 634463-13-1P 634463-23-3P
634463-44-0P 634463-55-1P 634463-77-7P
634463-93-7P 634463-97-1P 634464-03-2P
634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P
634464-29-2P 634464-34-9P 634464-39-4P
634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate
634470-24-9P 634470-42-1P 634525-08-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634462-48-9P 634464-71-4P 634469-50-4P,
1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-57-1P, tert-Butyl
[[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
634469-63-9P, 1-[2-[4-(2-Pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-68-4P
634469-69-5P 634469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
634469-86-6P, tert-Butylmethyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
634469-97-9P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d bib abs hitstr l17 tot
```

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:723424 HCAPLUS
DN 138:137143
TI Synthesis of N-substituted piperazinyl carbamoyl and acetyl derivatives of tetrahydropapaverine: Potent antispasmodic agents
AU Kaur, Jaskiran; Ghosh, Narendra Nath; Talwar, Anita; Chandra, Ramesh
CS Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, 110007, India
SO Chemical & Pharmaceutical Bulletin (2002), 50(9), 1223-1228
CODEN: CPBIAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 138:137143
GI



I

AB The synthesis and structure-activity-relationship (SAR) for a series of N-substituted piperazinyl carbamoyl and piperazinyl acetyl derivs. of tetrahydropapaverine have been carried out. The general synthetic methods of carbamoyl tetrahydropapaverine analogs involve N-substituted piperazines and carbamoyl imidazole tetrahydropapaverine as starting materials. Another route for synthesizing these compds., involving the formation of carbamoyl imidazole piperazine has also been explored. Acylation of tetrahydropapaverine followed by substitution with various piperazinyl moieties afforded the acetyl tetrahydropapaverine derivs. Variously substituted piperazines have been used to monitor the effect of electron releasing and electron withdrawing substituents upon the antispasmodic activity of the mols. Effect of varying electron densities on the antispasmodic activity, by altering the position of these groups on the benzene ring has also been monitored. Pharmacol. methods involve the in vitro antispasmodic activity studies on a freshly removed guinea pig ileum using a force displacement transducer amplifier connected to a physiograph. Among the analogs synthesized in the present study, a promising compound I, a potent muscle relaxant as compared to papaverine, has been obtained.
IT 492464-25-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of N-substituted piperazinyl carbamoyl and acetyl derivs. of tetrahydropapaverine as antispasmodic agents)
RN 492464-25-2 HCAPLUS
CN Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[4-(2-pyrimidinyl)-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:594790 HCAPLUS
DN 111:194790
TI Preparation of N-[3-(heterocyclylcarbonyl- and -sulfonyl)propyl]-N'-2-pyrimidinylpiperazines as antianxiety agents
IN Welch, Willard Mckowan
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP----314363	A2	19890503	1988EP-0309725	19881017
	EP----314363	A3	19900711		
	EP----314363	B1	19930407		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO---8903831	A1	19890505	1987WO-US02855	19871026
	W: FI, HU, NO, SU, US				
	HU-----58724	A2	19920330	1987HU-0006036	19871026
	HU----206109	B	19920828		
	AI-----87919	T	19930415	1988AI-0309725	19881017
	ES---2054823	T3	19940816	1988ES-0309725	19881017
	IL-----88085	A	19930221	1988IL-0088085	19881019
	JP---01157979	A	19890621	1988JP-0268008	19881024
	JP---06043406	B	19940608		
	CN---1042148	A	19900516	1988CN-0107386	19881024
	CN---1022246	B	19930929		
	ZA----8807925	A	19900627	1988ZA-0007925	19881024
	DD----283388	A5	19901010	1988DD-0321032	19881024
	DD----298397	A5	19920220	1988DD-0337989	19881024
	CA---1314881	C	19930323	1988CA-0581091	19881024
	AU---8824327	A	19890427	1988AU-0024327	19881025
	AU----598161	B2	19900614		
	DK---8805914	A	19890427	1988DK-0005914	19881025
	DK----171788	B1	19970526		
	PL----152117	B1	19901130	1988PL-0275476	19881025
	PL----153184	B1	19910329	1988PL-0279558	19881025
	CS----274441	B2	19910411	1988CS-0007080	19881026
	CS----274446	B2	19910411	1989CS-0001351	19890302
	NO----9001652	A	19900411	1990NO-0001652	19900411
	US----4994455	A	19910219	1990US-0477835	19900421
	RU---2029768	C1	19950227	1990RU-4743942	19900425
	FI-----94638	B	19950630	1990FI-0002070	19900425
	FI-----94638	C	19951010		
PRAI	1987WO-US02855	A	19871026		
	1988EP-0309725	A	19881017		
	1988CS-0007080	A3	19881026		

OS CASREACT 111:194790; MARPAT 111:194790
GI



I

AB The title compds. (I; R2 = RCO, R1SO2; R = 14 specific N-attached heterocyclyl, e.g., pyrrolidino, piperidine, etc.; R1 = 7 specific N-attached heterocyclyl, e.g., 4,4-dimethylpiperidino, 4-(2-pyrimidinyl)piperazino, etc.) were prepared as antianxiety agents (no data). Br(CH2)3CO2Et was refluxed 4 h with H2O-separation with 1-(2-pyrimidinyl)piperazine in MeCOCH2CHMe2 containing Na2CO3 and KI to give 75% I (R2 = CO2Et) which was saponified and the product stirred 3 h at 0° and then overnight with 4,4-dimethylpiperidine in CH2Cl2 containing Et3N, 1-hydroxybenzotriazole, and DCC to give 47% I (R2 = 4,4-dimethylpiperidinocarbonyl).
IT 123319-56-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antianxiety agent)
RN 123319-56-2 HCAPLUS
CN Piperidine, 4-acetyl-1-[1-oxo-4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4-phenyl- (9CI) (CA INDEX NAME)

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 1-3 5 l21
```

L21 ANSWER 1 OF 5 USPATFULL on STN

AN 2007:43120 USPATFULL

TI 4-{(ARYLMETHYL)AMINOMETHYL}PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

IN Bosch, Michael, Marsillargues, FRANCE
Wagnon, Jean, Montpellier, FRANCE

PA sanofi-aventis, Paris, FRANCE (non-U.S. corporation)

PI US-20070037819 A1 20070215

AI 2006US-000420505 A1 20060526 (11)

RLI Continuation of Ser. No. 2004WO-FR0003066, filed on 30 Nov 2004, UNKNOWN

PRAI 2003FR-0000014172 20031201

DT Utility

FS APPLICATION

LREP ROSS J. OEHLER, SANOFI-AVENTIS U.S. LLC, 1041 ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 948

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 4-[(arylmethyl)aminomethyl]piperidine derivatives of general formula (I) ##STR1## in the form of a base or an addition salt with an acid, and also in the form of a hydrate or solvate, and their preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-31-3P 852936-32-4P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(1,3-thiazol-2-yl)methyl]methanamine trihydrochloride 852936-33-5P, (2-Furylmethyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-34-6P, (3-Furylmethyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-35-7P, [(5-Methyl-2-furyl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-36-8P, [(4,5-Dimethyl-2-furyl)methyl](methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine trihydrochloride 852936-37-9P, [(5-Chloro-2-furyl)methyl](methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-38-0P, [[1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl][(2-thienyl)methyl]amine 852936-39-1P, [[1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl][(3-thienyl)methyl]amine 852936-40-4P, 1-Phenyl-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]methanamine 852936-41-5P, [[1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl][(pyridin-2-yl)methyl]amine 852936-42-6P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-2-yl)methyl]methanamine 852936-43-7P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-3-yl)methyl]methanamine tetrahydrochloride 852936-44-8P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-4-yl)methyl]methanamine tetrahydrochloride 852936-45-9P, N-Methyl-1-(pyrazin-2-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]methanamine tetrahydrochloride 852936-46-0P, [(6-Methylpyridin-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-47-1P, [(3-Methyl-2-thienyl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine trihydrochloride 852936-48-2P 852936-49-3P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyrimidin-5-yl)methyl]methanamine 852936-50-6P, (1H-Imidazol-2-ylmethyl)(methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-

L21 ANSWER 1 OF 5 USPATFULL on STN (Continued)

(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-51-7P, (1H-Imidazol-5-ylmethyl)(methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine tetrahydrochloride 852936-52-8P, N-Methyl-1-(4-methyl-1H-imidazol-5-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]pyridin-4-yl]methyl]methanamine
(drug candidate; prepn. of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]ethanoyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 852936-54-0P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
(intermediate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine
(drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

RN 852936-29-9 USPATFULL

CN 4-Piperidinemethanamine, N-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 2 OF 5 USPATFULL on STN

AN 2006:196251 USPATFULL

TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

IN Bono, Francoise, Toulouse, FRANCE
Bosch, Michael, Marsillargues, FRANCE
Dos Santos, Victor, Valergues, FRANCE
Herbert, Jean-Marc, Tournefeuille, FRANCE
Nisato, Dino, Saint-Georges D'Orques, FRANCE
Tonnerre, Bernard, Vailhauques, FRANCE
Wagnon, Jean, Montpellier, FRANCE

PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)

PI US-20060167007 A1 20060727
US-----7294628 B2 20071113

AI 2003US-000516808 A1 20030605 (10)
2003WO-FR0001686 20030605
20041203 PCT 371 date

PRAI 2002FR-0000007001 20020607

DT Utility

FS APPLICATION

LREP ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., 1041 ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2;

R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4) alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;

R.sub.2 represents a hydrogen atom or a halogen atom;

R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8COR.sub.9; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17;

or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;

R.sub.4 represents the aromatic group 1,3-thiazol-2-yl of formula: ##STR2## Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634461-63-5P 634461-69-1P 634462-72-9P 634462-91-2P 634463-08-4P 634463-19-7P 634463-39-1P 634463-49-3P 634464-60-1P 634464-66-7P 634525-03-4P
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride 634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-pyrazinyl)-1-piperazinyl]-1-propanone oxalate 634461-29-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634461-52-2P 634461-57-7P 634461-73-7P 634461-76-0P 634461-81-7P 634461-87-3P 634461-93-1P 634461-99-7P 634462-26-3P 634462-32-1P 634462-38-7P 634462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]-1-ethanone dioxalate 634462-55-8P 634462-61-6P 634462-68-3P 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-

L21 ANSWER 2 OF 5 USPATFULL on STN (Continued)

(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P, 1-[4-[4-Chlorophenyl]-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate 634463-13-1P 634463-23-3P 634463-44-8P 634463-55-1P 634463-77-7P 634463-87-7P 634463-97-1P 634464-03-2P 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P 634464-29-2P 634464-34-9P 634464-39-4P 634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate 634470-24-9P 634470-42-1P 634525-08-9P
(NGF binding inhibitor; prepn. of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634462-48-9P 634464-71-4P 634469-50-4P, 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-61-5P, 1-[2-[4-(2-Pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-68-4P 634469-69-5P 634469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-86-6P, tert-Butylmethyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-97-9P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
(preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

RN 634461-23-7 USPATFULL

CN 4-Piperidinemethanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 2 OF 5 USPATFULL on STN (Continued)

L21 ANSWER 3 OF 5 USPATFULL on STN
AN 2005:203297 USPATFULL
TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
IN Bono, Francoise, Toulouse, FRANCE
Bosch, Michael, Marsillargues, FRANCE
Dos Santos, Victor, Valergues, FRANCE
Herbert, Jean-Marc, Tournefeuille, FRANCE
Nisato, Dino, Saint-Georges D'Orques, FRANCE
Tonnerre, Bernard, Vailhauques, FRANCE
Wagnon, Jean, Montpellier, FRANCE
PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)
PI US-20050176722 A1 20050811
AI 2003US-000516704 A1 20030605 (10)
2003WO-FR0001685 20030605
PRAI 2002FR-0000007001 20020607
DT Utility
FS APPLICATION
LREP SANOFI-AVENTIS, PATENT DEPARTMENT-MAIL CODE D-303A, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2; p is 1 or 2;

R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;
R.sub.2 represents a hydrogen atom or a halogen atom;
R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8COR.sub.9; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17;
or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;
R.sub.4 represents an aromatic group selected from: ##STR2##
the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634461-63-5P 634461-69-1P 634462-72-9P 634462-91-2P 634463-08-4P 634463-19-7P 634463-39-1P 634463-49-3P 634464-60-1P 634464-66-7P 634525-03-4P
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride 634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-(pyrazinyl))-1-piperazinyl]-1-propanone oxalate 634461-29-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634461-52-2P 634461-57-7P 634461-73-7P 634461-76-0P 634461-81-7P 634461-87-3P 634461-93-1P 634461-99-7P 634462-26-3P 634462-32-1P 634462-38-7P 634462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]-1-ethanone dioxalate 634462-55-8P 634462-61-6P 634462-68-3P 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-

L21 ANSWER 3 OF 5 USPATFULL on STN (Continued)
(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P, 1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate 634463-13-1P 634463-23-3P 634463-44-8P 634463-55-1P 634463-77-7P 634463-93-7P 634463-97-1P 634464-03-2P 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P 634464-29-2P 634464-34-9P 634464-39-4P 634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate 634470-24-9P 634470-42-1P 634525-08-9P
(NGF binding inhibitor; prepn. of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634462-48-9P 634464-71-4P 634469-50-4P, 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-63-9P, 1-[2-[4-(2-Pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-68-4P 634469-69-5P 634469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-86-6P, tert-Butylmethyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-97-9P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
(preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
RN 634461-23-7 USPATFULL
CN 4-Piperidinemethanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 3 OF 5 USPATFULL on STN (Continued)

L21 ANSWER 5 OF 5 USPAT2 on STN
AN 2006:196251 USPAT2
TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
IN Bono, Fran.cedilla.oise, Toulouse, FRANCE
Bosch, Michael, Marsillargues, FRANCE
Dos Santos, Victor, Valergues, FRANCE
Herbert, Jean-Marc, Tourneefuille, FRANCE
Nisato, Dino, Saint-Georges d'Orques, FRANCE
Tonnerre, Bernard, Vailhauques, FRANCE
Wagnon, Jean, Montpellier, FRANCE
PA Sanofi-Aventis, Paris, FRANCE (non-U.S. corporation)
PI US-----7294628 B2 20071113
WO--2003104226 20031218
AI 2003US-000516808 20030605 (10)
2003WO-FR0001686 20030605
20041203 PCT 371 date
PRAI 2002FR-0000007001 20020607
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Leeser, Erich
LREP Gupta, Balaram
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1971
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I)

##STR1## in which:

n is 1 or 2;
R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4) alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;
R.sub.2 represents a hydrogen atom or a halogen atom;
R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8COR.sub.9; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17;
or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;
R.sub.4 represents the aromatic group 1,3-thiazol-2-yl of formula:

##STR2##

Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634461-63-5P 634461-69-1P 634462-72-9P
634462-91-2P 634463-08-4P 634463-19-7P
634463-39-1P 634463-49-3P 634464-60-1P
634464-66-7P 634525-03-4P
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride
634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-(pyrazinyl))-1-piperazinyl]-1-propanone oxalate
634461-29-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634461-52-2P 634461-57-7P
634461-73-7P 634461-76-0P 634461-81-7P
634461-87-3P 634461-93-1P 634461-99-7P
634462-26-3P 634462-32-1P 634462-38-7P
634462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperazinyl]-1-[4-[3-

L21 ANSWER 5 OF 5 USPAT2 on STN (Continued)



L21 ANSWER 5 OF 5 USPAT2 on STN (Continued)
(trifluoromethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]-1-ethanone dioxalate 634462-55-8P 634462-61-6P
634462-68-3P 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P,
1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate 634463-13-1P 634463-23-3P
634463-44-8P 634463-55-1P 634463-77-7P
634463-93-7P 634463-97-1P 634464-03-2P
634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P
634464-29-2P 634464-34-9P 634464-39-4P
634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate
634470-24-9P 634470-42-1P 634525-08-9P
(NGF binding inhibitor; prepn. of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634462-48-9P 634464-71-4P 634469-50-4P,
1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
634469-63-9P, 1-[2-[4-(2-Pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-68-4P
634469-69-5P 634469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
634469-86-6P, tert-Butylmethyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
634469-97-9P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
(preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
RN 634461-23-7 USPAT2
CN 4-Piperidinemethanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

=> d bib abs hitstr 4 l21

L21 ANSWER 4 OF 5 USPATFULL on STN
AN 91:15162 USPATFULL
TI Anti-anxiety agents
IN Welch, Jr., William M., Mystic, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US------4994455 19910219
AI 1990US-000477835 19900421 (7)
1987WO-US0002855 19871026
19900421 PCT 371 date
19900421 PCT 102(e) date
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Richardson, Peter C., Ginsburg, Paul H., De Benedictis, Karen
CLMN Number of Claims: 13
ECL Exemplary Claim: 1,6
DRWN No Drawings
LN.CNT 557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Anti-anxiety agents; namely, 1-(heterocyclylcarbonyl)-3-[4-(2-pyrimidinyl)-1-piperazinyl]propanes and 1-(heterocyclylsulfonyl)-3-[4-(2-pyrimidinyl)-1-(piperazinyl)]propanes; and methods for their preparation and use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 123319-56-2P
(preparation of, as antianxiety agent)
RN 123319-56-2 USPATFULL
CN Piperidine, 4-acetyl-1-[1-oxo-4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4-phenyl- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 16:49:27 ON 22 JAN 2008)

     FILE 'REGISTRY' ENTERED AT 16:49:33 ON 22 JAN 2008
L1                STR
L2             22 L1
L3           2510 L1 FULL
                  SAV TEM J704C1/A L3
L4                STR L1
L5             10 L4 SAM SUB=L3
L6            161 L4 FULL SUB=L3
L7            143 L6 AND 46.150.18/RID
L8            140 L7 AND NC2NC2/ES

     FILE 'HCAPLUS' ENTERED AT 16:56:19 ON 22 JAN 2008
L9               1 US20050176722 /PN

     FILE 'REGISTRY' ENTERED AT 16:56:29 ON 22 JAN 2008

     FILE 'HCAPLUS' ENTERED AT 16:56:29 ON 22 JAN 2008
L10              TRA L9 1- RN :      228 TERMS

     FILE 'REGISTRY' ENTERED AT 16:56:29 ON 22 JAN 2008
L11           228 SEA L10
L12            69 L11 AND L8
L13            71 L8 NOT L12

     FILE 'HCAPLUS' ENTERED AT 16:56:49 ON 22 JAN 2008
L14              2 L12
L15              4 L13
                   SEL HIT RN 3-4

     FILE 'REGISTRY' ENTERED AT 16:58:11 ON 22 JAN 2008
L16              2 E1-2

     FILE 'HCAPLUS' ENTERED AT 16:59:23 ON 22 JAN 2008
                   SEL AN 3-4 L15
L17              2 E3-6 AND L15
L18              2 L15 NOT L17
L19              3 L14,L18

     FILE 'HCAOLD' ENTERED AT 17:00:37 ON 22 JAN 2008
L20              0 L8

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:00:45 ON 22 JAN 2008
L21              5 L8

=>
```